EHA 2021: Transplant Ineligible Myeloma Patients Do Better With the Addition of Daratumumab
Posted: Jun 28, 2021
EHA 2021: Transplant Ineligible Myeloma Patients Do Better With the Addition of Daratumumab image

 

At the recent European Hematology Association meeting, Jannsen Oncology shared results from the Phase III MAIA study showing that the daratumumab/Revlimid/dex combination was better than Revlimid/dex alone for overall survival and progression free survival. This study included newly diagnosed myeloma patients who were not eligible for a stem cell transplant. 

After a median follow-up of almost five years (56.2 months), there was a 32 percent reduction of risk of death in the Dara/Rev/dex arm compared to the Revlimid/dex arm. The progression-free survival showed a 47 percent reduction in risk of disease progression or death.

There has been some debate in the myeloma community about whether treatments like daratumumab should be held in "reserve" for later lines of treatment. This study shows that using daratumumab as one of the first treatments can significantly improve outcomes for newly diagnosed patients. Dr. Thierry Facon, MD, and Professor of Heamatology at Lille University Hospital in France said: 

"The treatment of multiple myeloma becomes more complex with each relapse. Therefore, it is critical to achieve deep treatment responses and improved survival with frontline therapy. These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma."

 

In the study of 737 newly diagnosed patients who were not eligible for transplant, they either received Dara/Revlimid/dex or Revlimid/dex. Patients were treated until disease progression or unacceptable toxicity. The average age of participants was 73. If patients on the Revlimid/dex arm relapsed and needed treatment, 46% of them were given daratumumab. 

  D-Rd Rd
Five-year overall survival 66% 53%
Five-year progression free survival 53% 29%
Median time to next treatment not reached 42.4 months
Overall response rate 93% 82%

 

No new safety concerns were identified in the triple combination group. 

Grade 3 or 4 side effects D-Rd Rd
Neutropenia 54% 37%
Pneumonia 19% 11%
Anemia 17% 22%
Lymphopenia 16% 11%

 

Based on earlier MAIA study results, the FDA previously approved Darzalex with Revlimid and dex for newly diagnosed, transplant ineligible patients. These study results just validate the importance of that approval and the use of a CD-38 monoclonal antibody for newly diagnosed myeloma patients as first-line treatment.  

 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811